Validation and Inverse Analysis of The Athletic Shoulder Test (ASH).

March 24, 2025 updated by: Pablo Hernandez-Lucas, University of Vigo

Validation and Inverse Analysis of The Athletic Shoulder Test (ASH): Reliability of a Novel Upper Body Isometric Strength Test

To validate both the Athletic Shoulder (ASH) test, conducted on rugby players, and its inverse, the Inverse Athletic Shoulder (IASH) test, for swimmers. This involves assessing the strength relationship between shoulder flexion and extension at three different adduction angles (180º, 135º, 90º) to identify potential injuries associated with these imbalances.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
21

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Pontevedra, Spain, 36004
        • Pablo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • High-performance swimmers.
  • Aged between 14 and 18 years.
  • No acute injuries in the cervical or scapular region.
  • Ability to perform the ASH and IASH tests without compensatory movements.

Exclusion Criteria:

  • Acute injuries in the cervical or scapular region.
  • Inability to maintain proper positioning during the tests due to lack of adequate mobility or strength.
  • Refusal to sign informed consent (or legal guardian's consent for minors).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Other: Validation of ASH and IASH Tests in Swimmers
Participants perform the Athletic Shoulder (ASH) test and the Inverse Athletic Shoulder (IASH) test to assess isometric shoulder strength at different adduction angles (180º, 135º, 90º) over two sessions. Data is collected to evaluate the reliability and validity of these tests for swimmers.
Procedure: Athletic Shoulder (ASH) and Inverse Athletic Shoulder (IASH) Tests
Participants perform the Athletic Shoulder (ASH) test and Inverse Athletic Shoulder (IASH) test to measure maximal isometric shoulder strength in three positions (180º, 135º, 90º) during two separate sessions. Data is used to assess test reliability and validity for high-performance swimmers.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Intraclass Correlation Coefficient (ICC) for ASH Test
Time Frame: Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Assessment of between-day reliability of the ASH test using intraclass correlation coefficients (ICC) for shoulder extension at three adduction angles (180º, 135º, 90º).
Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Intraclass Correlation Coefficient (ICC) for IASH Test
Time Frame: Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Assessment of between-day reliability of the IASH test using intraclass correlation coefficients (ICC) for shoulder flexion at three adduction angles (180º, 135º, 90º).
Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Coefficient of Variation (CV) for ASH and IASH Tests
Time Frame: Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Analysis of the coefficient of variation (CV) to evaluate data dispersion and consistency for both ASH and IASH tests.
Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Minimum Detectable Change (MDC) for ASH and IASH Tests
Time Frame: Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Calculation of the minimum detectable change (MDC) to identify the smallest significant change in performance beyond measurement error for both ASH and IASH tests.
Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Force Ratios Between ASH and IASH Tests
Time Frame: Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Evaluation of the agonist-antagonist strength ratios between ASH (extension) and IASH (flexion) tests across three adduction angles (180º, 135º, 90º).
Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Comparison of Shoulder Strength Between Preferred and Non-Preferred Breathing Sides
Time Frame: Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Analysis of differences in isometric shoulder strength between the preferred and non-preferred breathing sides in ASH and IASH tests across three adduction angles.
Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Evaluation of Test Fatigue and Its Impact on Reliability
Time Frame: Measured at two time points: baseline (Day 0) and follow-up (Day 2).
Assessment of fatigue effects during ASH and IASH tests, considering the 20-second rest period and total number of efforts (36 per participant), and their potential impact on test reliability and strength measurements.
Measured at two time points: baseline (Day 0) and follow-up (Day 2).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Vigo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 10, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 20, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 30, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 31, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 1, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 25, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 28, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 24, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • DASH

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings